Aignostics Raises $34 Million to Advance AI-Powered Pathology Solutions
Aignostics founders: Frederick Klauschen, Maximilian Alber, Klaus-Robert Müller, and Viktor Matyas © Aignostics
Aignostics, a Berlin-based artificial intelligence company specializing in computational pathology, has secured $34 million in Series B funding to advance its AI-powered precision medicine solutions. According to the company's announcement, the investment round was led by ATHOS, with significant participation from Mayo Clinic and High-Tech Gründerfonds (HTGF).
The funding will support three key initiatives: developing new product offerings for biopharmaceutical clients, expanding operations in the United States, and creating advanced foundation models for pathology in collaboration with Mayo Clinic.
The company's CEO and Co-Founder, Viktor Matyas, highlighted 2024 as a transformative year, noting the launch of their first foundation model, RudolfV, and a strategic partnership with Bayer. "With RudolfV, we've gained the ability to quickly develop cost-efficient algorithms that generalize to the real-world," Matyas stated.
Jim Rogers, CEO of Mayo Clinic Digital Pathology, emphasized the potential impact: "We know that digital pathology, paired with the vast capabilities of AI, has immense potential to impact diagnosis and treatment for patients."
The investment brings Aignostics' total funding to over $55 million, with participation from existing investors including Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and IBB Ventures.
Founded in 2018 as a spin-off from Charité Berlin, Aignostics focuses on transforming complex multimodal pathology data into actionable insights for drug development, translational research, and companion diagnostics development.
